Exelixis, Inc. (NASDAQ:EXEL) has received an average recommendation of “Buy” from the thirteen ratings firms that are covering the firm. Five equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $19.51.
Several research analysts have recently weighed in on the company. Zacks Investment Research cut Exelixis from a “buy” rating to a “hold” rating in a research report on Wednesday, March 1st. Oppenheimer Holdings Inc. reaffirmed a “market perform” rating on shares of Exelixis in a research report on Thursday, May 4th. TheStreet raised Exelixis from a “d” rating to a “c+” rating in a research report on Tuesday, May 2nd. Cann reaffirmed a “hold” rating on shares of Exelixis in a research report on Wednesday, April 19th. Finally, Stifel Nicolaus cut Exelixis from a “buy” rating to a “hold” rating and set a $22.00 price objective for the company. in a research report on Tuesday, February 28th. They noted that the move was a valuation call.
Exelixis (NASDAQ:EXEL) traded down 6.42% during trading on Tuesday, hitting $19.68. The company had a trading volume of 5,867,718 shares. Exelixis has a 12-month low of $5.70 and a 12-month high of $24.85. The company has a market capitalization of $5.76 billion, a price-to-earnings ratio of 937.14 and a beta of 1.78. The firm has a 50-day moving average of $21.41 and a 200 day moving average of $19.19.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, May 1st. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.06. The firm had revenue of $80.90 million for the quarter, compared to analyst estimates of $65.23 million. The firm’s quarterly revenue was up 425.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.27) earnings per share. On average, equities research analysts forecast that Exelixis will post $0.18 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was first published by sleekmoney and is owned by of sleekmoney. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://sleekmoney.com/exelixis-inc-exel-given-consensus-recommendation-of-buy-by-brokerages/1841217.html.
In related news, Director George Poste sold 76,250 shares of the company’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $22.53, for a total transaction of $1,717,912.50. Following the sale, the director now owns 86,405 shares in the company, valued at $1,946,704.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carl B. Feldbaum sold 32,988 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $21.58, for a total value of $711,881.04. Following the sale, the director now owns 52,721 shares in the company, valued at approximately $1,137,719.18. The disclosure for this sale can be found here. Insiders have sold 1,097,718 shares of company stock worth $24,364,853 in the last quarter. 5.90% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in EXEL. Fortaleza Asset Management Inc. bought a new stake in Exelixis during the first quarter valued at about $106,000. Pittenger & Anderson Inc. bought a new stake in Exelixis during the fourth quarter valued at about $149,000. Commerzbank Aktiengesellschaft FI bought a new stake in Exelixis during the fourth quarter valued at about $169,000. Meeder Asset Management Inc. bought a new stake in Exelixis during the first quarter valued at about $170,000. Finally, Laurion Capital Management LP bought a new stake in Exelixis during the third quarter valued at about $208,000. Institutional investors and hedge funds own 78.40% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/exelixis-inc-exel-given-consensus-recommendation-of-buy-by-brokerages/1841217.html
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.